Premium Nahrungsergänzungsmittel | artgerecht

Beta 2 Microglobulin - Function & Reference Values

Beta 2 microglobulin (B2M) is a small protein used as a blood and urine marker to assess kidney disease and certain cancers, including multiple myeloma.

Regular tips about health Regular tips about health

Things worth knowing about "Beta 2 Microglobulin"

Beta 2 microglobulin (B2M) is a small protein used as a blood and urine marker to assess kidney disease and certain cancers, including multiple myeloma.

What is Beta 2 Microglobulin?

Beta 2 microglobulin (abbreviated B2M or β2M) is a small protein with a molecular weight of approximately 11,800 daltons. It forms part of the MHC class I molecules (major histocompatibility complex) found on the surface of virtually all nucleated cells in the body, where it plays a key role in immune function. B2M is continuously shed from cell surfaces into the bloodstream in small amounts and is subsequently filtered and metabolized primarily by the kidneys.

Biological Function

Beta 2 microglobulin serves the following key functions in the human body:

Structural stabilization of MHC class I molecules on the cell surface
Support of antigen presentation to cytotoxic T lymphocytes
Participation in immune recognition of abnormal or virus-infected cells

Because B2M is produced by virtually all nucleated cells, its serum concentration reflects both the rate of cell turnover (especially of lymphocytes) and kidney function.

Clinical Significance as a Biomarker

Kidney Disease

Beta 2 microglobulin is freely filtered by the glomeruli of the kidney and reabsorbed and catabolized by more than 99% in the proximal tubular cells. When tubular function is impaired, B2M concentrations in the urine rise; when glomerular filtration is reduced, serum levels increase. Therefore, B2M serves as a sensitive marker for:

Early detection of tubular kidney damage (e.g., caused by medications, heavy metals, or inflammation)
Assessment of the glomerular filtration rate (GFR) in chronic kidney disease
Monitoring of kidney transplant function

Hematological Malignancies and Tumors

Elevated B2M levels in the blood are an important prognostic marker in several malignant conditions, particularly:

Multiple myeloma: B2M is a well-established prognostic marker. High levels correlate with a larger tumor cell mass and a worse prognosis. The International Staging System (ISS) for multiple myeloma is partly based on serum B2M levels.
Non-Hodgkin lymphomas and chronic lymphocytic leukemia (CLL): Elevated values indicate higher tumor burden.
Waldenstrom macroglobulinemia and other lymphoproliferative disorders

Inflammatory and Autoimmune Conditions

Since B2M is released in greater quantities during increased cell turnover -- including during inflammation and immune system activation -- elevated levels can also occur in chronic inflammatory conditions such as HIV infection, systemic lupus erythematosus, or rheumatoid arthritis.

Diagnosis and Measurement

Beta 2 microglobulin is typically measured using an immunoassay (e.g., ELISA or nephelometry) from serum, plasma, or urine. Reference values may vary slightly between laboratories:

Serum: Normal value usually < 2.5 mg/L
Urine: Normal value usually < 0.3 mg/L (spot urine) or < 0.37 mg/g creatinine

When interpreting results, it is important to note that elevated serum values can result from either reduced kidney function or increased cell proliferation. Careful clinical context is therefore essential for accurate interpretation.

Dialysis-Related Amyloidosis

In long-term dialysis patients, beta 2 microglobulin can accumulate in joints, tendons, and bones, leading to a condition known as dialysis-related amyloidosis. This complication arises because older dialysis methods remove B2M insufficiently. Modern high-flux dialysis membranes are more effective at clearing B2M and can reduce this risk.

Summary

Beta 2 microglobulin is a versatile biomarker with relevance in nephrology, oncology, and immunology. Measuring B2M in blood or urine helps detect kidney damage at an early stage, assess the course of hematological malignancies, and monitor treatment response.

References

Dispenzieri A. et al. - International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009.
National Kidney Foundation - K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease, 2002. Available at: www.kidney.org
World Health Organization (WHO) - Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition, IARC Press, Lyon, 2017.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.